<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Szabo, Csaba</dc:creator>
  <dc:date>2020-01-14</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Down syndrome (DS) is associated with significant perturbances in many  morphological and biochemical features. Cystathionine‐β‐synthase (CBS) is one of  the key mammalian enzymes that is responsible for the biological production of the  gaseous transmitter hydrogen sulfide (H2S). When H2S is overproduced, it can exert  detrimental cellular effects, in part due to inhibition of mitochondrial Complex IV  activity. An increased expression of CBS and the consequent overproduction of H2S  are well documented in individuals with DS. Two decades ago, it has been proposed  that a toxic overproduction of H2S importantly contributes to the metabolic and  neurological deficits associated with DS. However, until recently, this hypothesis has  not yet been tested experimentally. Recent data generated in human dermal  fibroblasts show that DS cells overproduce H2S, which, in turn, suppresses  mitochondrial Complex IV activity and impairs mitochondrial oxygen consumption and  ATP generation. Therapeutic CBS inhibition lifts the tonic (and reversible) suppression  of Complex IV: This results in the normalization of mitochondrial function in DS cells.  H2S may also contribute to the cellular dysfunction via several other molecular  mechanisms through interactions with various mitochondrial and extramitochondrial  molecular targets. The current article provides a historical background of the field,  summarizes the recently published data and their potential implications, and outlines  potential translational approaches (such as CBS inhibition and H2S neutralization)  and future experimental studies in this re‐emerging field of pathobiochemistry.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/308480</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/308480/files/cza_rpr.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/febs.15214</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>The FEBS Journal. - 2020, vol. 287, no. 15, p. 3150-3160</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">The re-emerging pathophysiological role of the cystathionine-β-synthase - hydrogen sulfide system in Down syndrome</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
